Speech by Federal President Dr. h. c. Joachim Gauck at a matinee celebrating the tenth anniversary of the Eva Luise and Horst Köhler Foundation for People with Rare Diseases on March 5, 2016 ...

Germany Joachim Gauck · Former Federal President of Germany

8 March 2016 · Matinee celebrating the tenth anniversary of the Eva Luise and Horst Köhler Foundation for People with Rare Diseases

Context
Gauck addressed a matinee on March 5, 2016, celebrating the tenth anniversary of the Eva Luise and Horst Köhler Foundation for People with Rare Diseases and honoring prize recipients.
Main themes
Rare diseases research, Eva Luise and Horst Köhler Foundation anniversary, scientific progress and medical advances, philanthropy and civil engagement, networking and specialized medical centers, research prizes and scholarships, national action plan for rare diseases, European Union health policy, patient advocacy, foundations in Germany
Duration
~13 min
47th percentile
Words
1,604
47th percentile
Sentences
78
51st percentile
Readability
45
49th percentile
Grade
11.9
43rd percentile
Syntax
3.01
49th percentile
Vocabulary
2.03
15th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 82%82%
  • Ceremonial 14%14%
  • Geopolitical 3%3%
  • Institutional 1%1%
  • Economic 0%0%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 0%

78 sentences in 17 paragraphs

I am very pleased to be here with you today. There are two reasons for congratulations. We honor award winners, and at the same time, we honor the donors for their merits that inspire hope – hope for something that connects everyone here in the room: progress in the fight against rare diseases.

We will learn later who is being awarded the Eva Luise Köhler Prize and what distinguishes the work of the awardee. But let me mention at this point why the recipients of this prize stand out: because they research with the conviction that all people, including those with rare diseases, should benefit from scientific progress.

However, this requires support – support like that provided by the Eva Luise and Horst Köhler Foundation. Researching, networking, healing – this triad, dear Mrs. Köhler, dear Mr. Köhler, you have laid as the foundation of your foundation for people with rare diseases, by the way, the first foundation of its kind in Germany. I sincerely congratulate you on your tenth anniversary!

I would also like to point out that many people in Germany are actually just waiting to be inspired to discover the potential within themselves to do good. The media recently reported that people in Germany have donated more than ever before. This is a great signal that in this country, we cannot satisfy our souls merely by being economically successful and that we also need to represent everything possible in politics. The country needs additional opportunities to believe in itself, to adorn itself, to take itself seriously. That is why it is so important that we illuminate the spaces together where even more human engagement is required. And that is why I want to take this opportunity to explicitly praise and highlight the work of foundations in the country. Now I return to your very special foundation.

It was not a given to discover and bring to light a new field and to present it to the public eye. Because many people think: "We have responsible parties. We have institutions and foundations and engaged citizens." But then suddenly something arises where one feels: "Here I am particularly challenged." And so it is important for me to commend you for enriching this network for rare diseases with an important project. Most rare diseases cannot be cured so far. From this painful experience, your foundation's initiative has emerged. And if there is no cure, then it is all the more important to find therapies to alleviate suffering. That is why it is so important that more research is conducted into the causes and treatment options for rare diseases.

With your research prize, dear Mr. and Mrs. Köhler, you have contributed to more scientists dedicating themselves to deciphering and treating such diseases. And thanks to your financial support, promising progress has already been made in the development of medicinal treatment forms. But there is still pioneering work to be done. Young researchers are particularly called upon here – those for whom you want to set additional incentives in the future by awarding scholarships.

Providing help to people with rare diseases is a matter close to your heart. Even before you, dear Mrs. Köhler, founded the foundation together with your husband, you took on the patronage of "ACHSE," the "Alliance of Chronic Rare Diseases." Practically since the beginnings of this network, you have been helping to give a voice to people with rare diseases. And fortunately, there are more and more voices that are also finding more and more ears.

Thanks to the great efforts of many engaged individuals, it has been possible in the ten years of your foundation's work to raise awareness that people with rare diseases need special support. This is also through actions like the "Rare Disease Day," which was celebrated just last week in numerous places and institutions. There are also advances in medical infrastructure. Since the first German center for rare diseases was established in Freiburg in 2009, around two dozen specialized facilities have been created at German university hospitals that are dedicated to the research and treatment of rare diseases. Often, these centers are the only places that can offer patients a prospect of help.

For the transfer of expert knowledge, networking now plays a key role in the fight against rare diseases. Here, thankfully, there are also developments that are encouraging. For example, when we think of the establishment of the National Action Alliance "NAMSE." The "National Action Plan for People with Rare Diseases," which the alliance partners adopted three years ago, includes more than fifty measures and projects. So there are ambitious goals, foremost among them the aim of creating a network of certified specialized centers, where expertise should be bundled and more intensive research should be enabled.

Let me remind you at this point that it was the European Union that recommended action plans for rare diseases to the member states. In fact, the European Union has played a pioneering role in recent years in efforts to help patients suffering from rare diseases. I believe that such good results of European cooperation should be acknowledged, especially at a time when it is fashionable to portray the European Union in a particularly negative light.

Despite successful projects for the treatment of rare diseases, there is still much to be done. A glance at the interim report on the implementation of the national action plan suffices. Much takes time because there are still so many white spots on the map for rare diseases. Many of you here in the room know what this means from your own painful experience. I am grateful that you are attending this anniversary event. You, the patients, know what it is like to live between hope and fear. You have experienced what it means to live in uncertainty about a disease for years. What it feels like to be analytically dissected into a multitude of findings and medical data – only to find out in the end that there is a name for your disease, but no therapy yet. Most of us who do not suffer from a rare disease can only guess how exhausting this must be, by the way, also for the relatives.

We are used to categorizing illness; that is how our healthcare system works. Treatments are standardized, processes are structured, billing is precisely defined. Rare diseases fit into this system only with great difficulty, despite some reforms. Above all, rare diseases often do not conform to the expectation that being ill is merely an interruption, that health will soon be restored, and that life will then continue as usual. Being treated instead of being able to act for oneself – for many people with rare diseases, this experience is life-defining.

The longing for progress in research is therefore all too understandable, especially since the terrible diagnosis of "incurable" also affects many children. But studies involving children and adolescents also provide encouragement because they show that research collaborations can lead to successes, sometimes even breakthroughs. I therefore want to encourage all those engaged to continue their efforts, and if possible, to intensify them. The collaboration between research and self-help is indispensable.

I would wish that your commitment, Mrs. Köhler, and the commitment of so many people here in the room, would reach even further circles. It has been shown that more research is conducted where patient organizations are involved as a driving force, where they can convey their lived knowledge about rare diseases to researchers. Self-help associations also help to find patients for clinical studies. When I hear how much effort it took, for example, to recruit 300 participants for a study on a rare metabolic disease – and that the patients came from twenty countries on four continents, it shows how important collaboration between researchers and affected individuals is, even across national borders.

The dialogue between science and self-help organizations also seems essential to me for another reason. There are great expectations that with the help of innovative methods, such as molecular biology, gene medicine, and neuroscience, it will be possible to cure or even prevent rare diseases. "Personalized medicine" is the magic word. This research, as we all know, also brings great responsibility. Where science delves into genetic information, where it researches and possibly alters cognitive abilities and brain processes, fundamental ethical questions arise: What understanding will we have in the future of the personality and autonomy of sick individuals? What should be done when the right to know and not to know about hereditary diseases come into conflict? This difficult dialogue challenges us all – science, civil society, and politics – because it is about nothing less than our understanding of humanity.

The modern possibilities of exploring fundamental human structures give us hope that we will succeed in discovering new paths to healing, especially for people with rare diseases. But alongside the necessary scientific efforts, I want to emphasize here at the end – something must always be added, something that connects all of you here in the room: I mean the willingness to shape life paths that are overshadowed by illness and suffering with united efforts. And by doing so, you convey an important message to all of us: to recognize in every patient, whether suffering from a rare or a common disease, not just the sick person, but always the human being.

To you, dear Eva Luise Köhler, and to you, dear Horst Köhler, as well as to all your fellow campaigners, I express my heartfelt thanks on this anniversary day for your tireless commitment, for your generosity, and above all for your love of humanity.